<DOC>
	<DOCNO>NCT02253186</DOCNO>
	<brief_summary>The objective study assess effect new Armsleeve , worn night maintenance phase upper limb lymphoedema treatment combination Day-time usual lymphology hosiery .</brief_summary>
	<brief_title>Clinical Study Assess Safety Efficacy New Armsleeve Management Arm Lymphoedema</brief_title>
	<detailed_description />
	<mesh_term>Lymphedema</mesh_term>
	<criteria>Unilateral secondary upper limb lymphoedema stage II III , follow breast cancer Patients hospitalize intensive phase decongestive lymphoedema therapy ( DLT ) decrease lymphoedema volume achieve hospitalization Lymphoedema evident pit sign ( assessed ++ +++ ) Requiring compression therapy , least , next 3 month . Affected arm fit one 6 standard size AutoAdjustable MOBIDERMÂ® armsleeve provide . Signed informed consent prior studymandated procedure . Not administrative legal supervision . Covered health insurance system Stage I lymphoedema Active cellulitis Lymphoedema associate active cancer need acute chemotherapy Motor sensitive neurological deficiency Postoperative oedema ( i.e acute oedema follow breast cancerrelated surgery ) Patient participate clinical study Unlikely follow 3 month clinical assessment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>